Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Aminopeptidase N (CD13), Mouse anti-Human, Clone: 452, Millipore Sigma™
Mouse Monoclonal Antibody
Supplier: MilliporeSigma MABF2147100UG
Description
Anti-Aminopeptidase N (CD13), clone 452, Cat. No. MABF2147, is a mouse monoclonal antibody that detects Aminopeptidase N and has been tested for use in Flow Cytometry, Immunocytochemistry, Immunoprecipitation, Agonist function, and Western Blotting.
Aminopeptidase N (UniProt: P15144; also known as EC:3.4.11.2, AP-N, hAPN, Alanyl aminopeptidase, Aminopeptidase M, AP-M, Microsomal aminopeptidase, Myeloid plasma membrane glycoprotein CD13, gp150, CD13) is encoded by the ANPEP (also known as APN, CD13, PEPN) gene (Gene ID: 290) in human. Aminopeptidase N is a single-pass type II membrane protein that is also found as a soluble form in cells. It is widely expressed as a homodimer of 280 kDa on the cell surface in many tissues, including intestinal epithelia and the nervous system. It serves as a broad specificity aminopeptidase that plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. It preferentially cleaves N-terminus neutral amino acids, most notably alanine residue. Aminopeptidase N is involved in many physiological processes, including antigen presentation regulation, differentiation, proliferation, apoptosis, cancer metastasis, and angiogenesis. It is also involved in the processing of various peptides including peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. Human Aminopeptidase N consists of a short N-terminal cytoplasmic end (aa 2-8), a transmembrane domain (aa 9-32), and a large extracellular portion (aa 33-967), which is composed of a Ser/Thr-rich region (aa 33-68) and the metalloprotease domain (aa 69-967).
Specifications
Aminopeptidase N (CD13) | |
Monoclonal | |
Unconjugated | |
Purified mouse monoclonal antibody IgG1 in PBS without azide. | |
ANPEP;APN;CD13;PEPN | |
Isolated human dermal fibroblasts. | |
100 μg | |
Inflammation & Immunology | |
NP_001141 | |
Human | |
Purified |
Flow Cytometry, Immunocytochemistry, Immunoprecipitation, Inhibition Assays, Western Blot | |
452 | |
Immunocytochemistry Analysis: A representative lot detected Aminopeptidase N (CD13) in Immunocytochemistry applications (Rahman, M.M., et. al. (2014). Front Physiol. 4:402; Subramani, J., et. al. (2013). J Immunol. 191(7):3905-12).Flow Cytometry Analysis: A representative lot detected Aminopeptidase N (CD13) in Flow Cytometry applications (Subramani, J., et. al. (2013). J Immunol. 191(7):3905-12).Western Blotting Analysis: A representative lot detected Aminopeptidase N (CD13) in Western Blotting applications (Rahman, M.M., et. al. (2014). Stem Cells. 32(6):1564-77; Rahman, M.M., et. al. (2014). Front Physiol. 4:402).Agonist Analysis: A representative lot induced a temporal increase in phosphorylation of FAK, ERK and Src kinases in U937 cells. (Subramani, J., et. al. (2013). J Immunol. 191(7):3905-12).Immunoprecipitation Analysis: A representative lot immunoprecipitated Aminopeptidase N (CD13) in Immunoprecipitation applications (Subramani, J., et. al. (2013). J Immunol. 191(7):3905-12). | |
AP-N;hAPN;Alanyl aminopeptidase;Aminopeptidase M;AP-M;Microsomal aminopeptidase;Myeloid plasma membrane glycoprotein CD13;gp150;CD13 | |
Mouse | |
Protein G purified | |
RUO | |
Primary | |
Clone 452 specifically detects Aminopeptidase N (CD13) in human cells. | |
Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. | |
IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction